Oligonucleotides News and Research

RSS

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.

Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases

A review in Cell Reports Medicine examines how advances in oligonucleotide chemistry and delivery have established ASOs and RNA interference therapies as a class of genetic medicines, with 21 oligonucleotides approved at the time of writing. It also identifies extrahepatic delivery, safety, target validation, individualized treatment, and data quality as priorities as the field expands into common diseases and explores AI-assisted development.

24 Sep 2026

Advancing intracellular delivery with LumiPore®: A new approach to cell transfection and drug discovery

Discover how LumiPore improves intracellular delivery with gentle, high-efficiency transfection for drug discovery and cell therapy research.

From Trince 8 Sep 2026

UCSF scientists build largest molecular interaction map for autism

For more than two decades, researchers have identified hundreds of genes that increase the risk of autism spectrum disorder (ASD).

28 Aug 2026

New study identifies key pathway for delivering antisense cancer drugs

Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer.

11 Aug 2026

RNA-based therapeutic strategy targets brain pathway behind cancer-associated cachexia

A new path has opened toward stopping cancer-associated cachexia, a devastating complication that gradually wastes patients away.

2 Aug 2026

Rice University chemists develop cheaper way to synthesize drugs

Pharmaceutical drugs often rely on chemical compounds found in the body. Take phosphate, a common compound cells use as a chemical switch.

29 Jul 2026

Tailored gene therapy dramatically reduces childhood epilepsy seizures in trial

SCN2A‑related developmental epileptic encephalopathy (DEE) is a rare, severe form of childhood epilepsy and one of the most common causes of monogenic autism.

21 Jul 2026

DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

DNA Script, the programmable biology company developing next-generation enzymatic DNA synthesis (EDS) technologies, today announced a new distribution agreement with Imperial Life Sciences (ILS), expanding access to the Company's SYNTAX platform across India.

From DNA Script 17 Jul 2026

Silver nanoparticles enable precise DNA cutting and assembly

DNA is composed of long chains that act as the blueprint for living organisms. In genetic engineering, scientists cut DNA at specific sites and join the resulting fragments to other DNA sequences, enabling applications such as advanced crop breeding, genetic disease treatment, and the generation of animal models for drug discovery.

10 Jun 2026

4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing

4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.

From 4basebio PLC 29 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

Study provides roadmap for safer pharmaceutical analysis methods

A new doctoral thesis at Karlstad University provides increased understanding of how medicines can be analysed more reliably and safely.

28 Apr 2026

Antisense oligonucleotides reverse rare neurodevelopmental disorder in preclinical models

Scientists at St. Jude Children's Research Hospital have found they can reverse the effects of HNRNPH2-related neurodevelopmental disorder using antisense oligonucleotides (ASOs) in preclinical models. ASOs are short synthetic nucleic acid strands that target specific messenger RNA.

22 Apr 2026

Early genomic testing prevents years of inconclusive visits for pediatric patients

For many families, eight years of uncertainty meant repeated specialist visits, inconclusive genetic tests and the growing fear that a clear answer might never come. For nearly half of the children enrolled in the Telethon Undiagnosed Disease Program (TUDP), that wait is now over.

21 Apr 2026

Why clinical proteomics faces a mass spectrometry vs. high-throughput profiling dilemma

This Clinical Chemistry and Laboratory Medicine review examines a central challenge in precision medicine: whether medical laboratories should prioritize metrologically sound, proteoform-resolving protein quantification by mass spectrometry or adopt scalable, affinity-based proteome profiling platforms built for high-throughput discovery and machine learning. It concludes that while emerging proteomics technologies expand diagnostic possibilities, careful validation, standardization, and quality assurance will be essential, with a hybrid path likely offering the most practical way forward.

19 Apr 2026

Novel compound clears harmful protein, protects neurons in frontotemporal dementia models

New research from Washington University School of Medicine in St. Louis adds to growing evidence that helping brain cells break down and eliminate their own cellular waste is a promising treatment strategy for a variety of neurodegenerative diseases.

31 Mar 2026

New initiative aims to scale individualized therapies for rare diseases

Critical Path Institute (C-Path) today announced the launch of One to Millions, a global, multi-stakeholder public-private initiative to enable scalable development of advanced therapies for highly individualized conditions.

26 Mar 2026

Existing medication could improve the health of people living with HIV

HIV exhausts the body's immune system by overactivating it, despite effective antiviral treatment.

23 Mar 2026

Targeting protein fragment may improve Huntington disease treatments

Treatments that target a fragment of the mutant protein that causes Huntington's disease might be more effective than treatments, now in clinical trials, that target the whole protein but leave this fragment intact, a new study in mice suggests.

18 Mar 2026

DNA Script expands global access to on-demand DNA synthesis with distributor agreements in Latin America and East Asia

DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced it has signed distribution agreements with Gencell, Bio-Medical Science Co. (BMS), and BioStream Co., expanding global access to the Company's SYNTAX® platform for decentralized, in-house and on-demand oligonucleotide production.

From DNA Script 18 Mar 2026

Oligonucleotides News and Research

Further Reading

Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases

Advancing intracellular delivery with LumiPore®: A new approach to cell transfection and drug discovery

UCSF scientists build largest molecular interaction map for autism

New study identifies key pathway for delivering antisense cancer drugs

RNA-based therapeutic strategy targets brain pathway behind cancer-associated cachexia

Rice University chemists develop cheaper way to synthesize drugs

Tailored gene therapy dramatically reduces childhood epilepsy seizures in trial

DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

Silver nanoparticles enable precise DNA cutting and assembly

4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing

How antibody-drug conjugates are redefining targeted cancer therapy

Study provides roadmap for safer pharmaceutical analysis methods

Antisense oligonucleotides reverse rare neurodevelopmental disorder in preclinical models

Early genomic testing prevents years of inconclusive visits for pediatric patients

Why clinical proteomics faces a mass spectrometry vs. high-throughput profiling dilemma

Novel compound clears harmful protein, protects neurons in frontotemporal dementia models

New initiative aims to scale individualized therapies for rare diseases

Existing medication could improve the health of people living with HIV

Targeting protein fragment may improve Huntington disease treatments

DNA Script expands global access to on-demand DNA synthesis with distributor agreements in Latin America and East Asia

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics